Efficacy of single-dose evolocumab injection in early-phase acute myocardial infarction: a retrospective single-center study
Yongcheol Kim, Ji Woong Roh, Oh-Hyun Lee, Seok-Jae Heo, Eui Im, Deok-Kyu Cho, Byeong-Keuk Kim
Korean J Intern Med. 2024;39(5):793-800. Published online 2024 Jun 24 DOI: https://doi.org/10.3904/kjim.2024.080
Citations to this article as recorded by 
Short-term effects of PCSK-9 inhibitors on percutaneous coronary intervention in patients with acute coronary syndrome
Dong Hyun Gim, In Young Choi, Young-Jae Ki, Hyun Kuk Kim, Sung Soo Kim, Keun-Ho Park, Heesang Song, Dong-Hyun Choi
The Korean Journal of Internal Medicine.2025; 40(3): 438. CrossRef
Real-World Safety and Effectiveness of Evolocumab in Korean Patients with Atherosclerotic Cardiovascular Disease or Familial Hypercholesterolemia: A Post-Marketing Surveillance Study
Donggyu Moon, Seung-Ho Hur, Sang-Rok Lee, Myung Ho Jeong, Kyung Hoon Cho, Osung Kwon, JinSeon Jeong, Ki Dong Yoo
Cardiology and Therapy.2025;[Epub] CrossRef
Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in patients after percutaneous coronary intervention: a systematic review and meta-analysis
Zhantao Cao, Ningjing Chen, Jun Chen, Xuejing Xu, Zhanglu Zhang, Yunsu Wang
Frontiers in Cardiovascular Medicine.2025;[Epub] CrossRef
PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression
Maram H. Abduljabbar
Pharmaceuticals.2024; 17(12): 1581. CrossRef